Glucosamine & Chondroitin Sulfate

Verify with FDA CVM →

27 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
4
Deaths Reported
1480.0%
Death Rate

Active Ingredients

Glucosamine & Chondroitin Sulfate

Administration Routes

OralUnknown

Species Affected

Dog 27

Most Affected Breeds

Retriever - Labrador 6
Retriever - Golden 3
Dog (unknown) 2
Mixed (Dog) 1
Terrier - Yorkshire 1
Lhasa Apso 1
Terrier - Jack Russell 1
Shih Tzu 1
Boxer (German Boxer) 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Vomiting 8
Lethargy (see also Central nervous system depression in 'Neurological') 6
Decreased appetite 5
Anorexia 4
Elevated total bilirubin 4
Ataxia 3
Abnormal ultrasound finding 3
Elevated serum alkaline phosphatase (SAP) 3
Elevated liver enzymes 3
Other abnormal test result NOS 3
Drooling 2
Seizure NOS 2

Outcome Breakdown

Ongoing
14 (51.9%)
Outcome Unknown
5 (18.5%)
Recovered/Normal
4 (14.8%)
Euthanized
2 (7.4%)
Died
2 (7.4%)

Data Summary

Metric Value
Total adverse event reports 27
Reports involving death 4
Case-fatality rate (reported events) 1480.0%
Distinct species in reports 1
Distinct breeds in reports 19
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine & Chondroitin Sulfate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 27 adverse event reports referencing Glucosamine & Chondroitin Sulfate, including 4 reports in which the animal died — a 1480.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine & Chondroitin Sulfate. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine & Chondroitin Sulfate reports are Dog (27 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (6), Retriever - Golden (3), Dog (unknown) (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine & Chondroitin Sulfate are Vomiting (8), Lethargy (see also Central nervous system depression in 'Neurological') (6), Decreased appetite (5), Anorexia (4). Of the 27 reports with a coded outcome, Ongoing is the leading category at 51.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine & Chondroitin Sulfate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial